GlassScriptPhysician profile
Michelle A Levin
NPI 1598891368
$8,185.01
in general payments reported to CMS, 2019-2025
43 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $588 · 2021: $913 · 2022: $1,571 · 2023: $1,081 · 2024: $821 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.81 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,920.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $839.05 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $773.43 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $520.70 | 2019-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $514.78 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $479.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $365.06 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $260.65 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $254.38 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $253.90 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $238.64 | 2021-2025 | Minimed 780g, Propel |
| Companion Medical, INC. | $182.31 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $137.90 | 2021-2025 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $130.92 | 2019-2020 | |
| Mannkind Corporation | $130.86 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.